logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore

prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Bliss GVS Pharma Ltd

Bliss GVS Pharma

Small Cap831 EmployeesIPO 2010
Current Price
213.92
1.87 (0.88%)Updated
NSE :BLISSGVS
BSE :506197
Today's Range
204.00
213.92
union icon
215.44
52 Week Range
52W Low108.12
52W High243.90
213.92
union icon
Downside97.85%
Upside14.01%

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
2,448.49 Cr
Market Cap
Total market value of company
P/E Ratio
22.44
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
1.42
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
10.18
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
3.92%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
11.70%
ROCE
Return on Capital Employed. >15% is good
Net Margin
12.57%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-3.37%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
3.27%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
13.00%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
108.00%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.08
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
99.68
Book Value
Net asset value per share
Dividend Yield
0.22%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
35.40%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • Quarterly profit growth of 108% indicates strong recent performance.
  • Healthy operating profit margin of 12.35% reflects operational efficiency.

Weaknesses

5 points
  • Promoter holding is relatively low at 35.4%, raising governance concerns.
  • Significant historical volatility in profitability and stock price observed.

Opportunities

4 points
  • Increasing global healthcare expenditure drives demand for pharmaceutical products.
  • Growing demand for generic drugs and contract manufacturing services globally.

Threats

4 points
  • Intense competition from larger, established pharmaceutical players limits market share.
  • Stringent and evolving regulatory landscapes increase compliance costs and hurdles.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

StandaloneAnnualAll amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

Recent Insider Transactions

Insider NameTransaction DateFiling DateTotal SharesChangePriceAction
Mr. Narsimha Shibroor Kamath
19 Feb 202521 Feb 20253.24 Cr
23,000
₹133.59BUY
Mr. Narsimha Shibroor Kamath
18 Feb 202521 Feb 20253.24 Cr
77,000
₹127.52BUY
Mrs. Vibha Gagan Sharma
21 Mar 202524 Mar 202525.75 L
25,000
₹122.63BUY
Mrs. Vibha Gagan Sharma
20 Mar 202524 Mar 202525.50 L
75,000
₹120.63BUY
Mr. Gagan Harsh Sharma
21 May 202523 May 202578,863
37,258
₹121.2BUY
Mr. Gagan Harsh Sharma
20 May 202523 May 202541,605
41,605
₹121.47BUY
Mr. Gagan Harsh Sharma
22 May 202526 May 202583,570
4,707
₹121.48BUY
Mr. Gagan Harsh Sharma
10 Jun 202512 Jun 20251.32 L
1,970
₹136.73BUY
Mr. Gagan Harsh Sharma
09 Jun 202512 Jun 20251.30 L
46,657
₹136.7BUY

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4241.12+₹27.20+12.72%
R3229.68+₹15.76+7.37%
R2222.56+₹8.64+4.04%
R1218.24+₹4.32+2.02%
PIVOT211.12-2.80-1.31%
CURRENT213.92--
S1183.92-₹30.00-14.02%
S2195.36-₹18.56-8.68%
S3199.68-₹14.24-6.66%
S4206.80-₹7.12-3.33%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
9.57L
(02 Mar 2026)
-76.2% vs avg
Delivery %
29.5%
(02 Mar 2026)
-0.3% vs avg
Avg Volume (20D)
4.03M
(03 Feb - 02 Mar)
20-day average
Avg Delivery %
29.8%
(03 Feb - 02 Mar)
Trend ↓
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Solara Active Pharma Sciences Ltd
178.00 %
Highest Dividend Yield
Jagsonpal Pharmaceuticals Ltd
1.44 %

Peer Comparison

Company Name
AMRUTANJAN
Amrutanjan Health Care Ltd
BAJAJHCARE
Bajaj Healthcare Ltd
BETA
Beta Drugs Ltd
GUFICBIO
Gufic BioSciences Ltd
HIKAL
Hikal Ltd
INDOCO
Indoco Remedies Ltd
IOLCP
IOL Chemicals & Pharmaceuticals Ltd
JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd
LINCOLN
Lincoln Pharmaceuticals Ltd
MOREPENLAB
Morepen Laboratories Ltd
NGLFINE
NGL Fine Chem Ltd
ORCHPHARMA
Orchid Pharma Ltd
RPGLIFE
RPG Life Sciences Ltd
SIGACHI
Sigachi Industries Ltd
SMSPHARMA
SMS Pharmaceuticals Ltd
SOLARA
Solara Active Pharma Sciences Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
SYNCOMF
Syncom Formulations (India) Ltd
THEMISMED
Themis Medicare Ltd
TTKHLTCARE
TTK Healthcare Ltd
UNICHEMLAB
Unichem Laboratories Ltd

About

BLISSGVS

Bliss GVS Pharma Ltd

Bliss GVS Pharma Limited is a pharmaceutical company headquartered in Mumbai, India, established in 1984. Their core business centers around the development, manufacture, and marketing of a diverse range of pharmaceutical formulations both domestically within India and internationally through exports.

The company's product portfolio is extensive and encompasses a wide spectrum of dosage forms. This includes capsules, tablets (including effervescent), injections, suspensions, liquids, creams, ointments, gels, eye and ear drops, suppositories, pessaries, transdermal patches, and other topical preparations like lotions, balms, and sprays. They also produce various other healthcare products such as soaps, shampoos, nasal inhalers, and personal care items.

Bliss GVS's therapeutic areas covered are equally broad, reflecting their commitment to providing a comprehensive range of medications. Their offerings include products addressing pain relief (analgesics), digestive issues (antacids, anti-diarrheals, anti-emetics), infections (antibacterials, antifungals, anti-infectives), respiratory ailments (cough syrups, nasal decongestants), cardiovascular conditions, and many other therapeutic categories. This spans anti-diabetic, anti-inflammatory, anti-malarial, anti-helminthic and numerous other therapeutic areas, along with products for specific conditions such as erectile dysfunction, laryngitis, and pharyngitis. Furthermore, they offer health supplements, vitamins, and other over-the-counter (OTC) products.

In addition to their core pharmaceutical offerings, Bliss GVS expands into related health and personal care areas. They provide products like health and nutritional supplements, vitamin supplements, amino acid preparations, iron tonics, insect repellants, moisturizers, and vaginal hygiene products. This diversification demonstrates a strategy to cater to a wider consumer base beyond prescription medications.

COMPANY FACTS - BLISSGVS

Registered Address

102, Hyde Park, Saki-vihar Road, Andheri-East

Mumbai

MAHARASHTRA

IN

Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 831

IPO Date: 26/07/2010

MANAGEMENT - BLISSGVS

Mr. Narsimha Kamath

Chief Executive Officer

Mr. Deepak Sawant

Chief Financial Officer

Ms. Aditi Bhatt

Compliance Officer, Company Secretary

Mr. Gagan Sharma

Managing Director, Executive Director

Ms. Shruti Rao

Whole-Time Director

Ms. Vibha Sharma

Whole-Time Director

Ms. Shilpa Bhatia

Independent Woman Director

Mr. Santosh Parab

Independent Director

Dr. Nandkumar Chodankar

Additional Non-Executive Independent Director

Investor Questions Answered

Bliss GVS Pharma Ltd (BLISSGVS) Stock FAQs

Get answers to the most common questions about Bliss GVS Pharma Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Bliss GVS Pharma Ltd (BLISSGVS) is ₹213.92. Today, the stock has gained by ₹1.87 (0.88%), trading in a range of ₹204 to ₹215.44. The stock opened at ₹204 with a trading volume of 9,57,140 shares.
Bliss GVS Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,448.49 crores, P/E ratio of 22.44, ROE of 3.92%, and ROCE of 11.70%. The dividend yield stands at 0.22%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Bliss GVS Pharma Ltd (BLISSGVS) is ₹243.9, while the 52-week low is ₹108.12. Currently trading at ₹213.92, the stock is 77.9% away from its 52-week low and 12.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Bliss GVS Pharma Ltd stock at ₹213.92 depends on multiple factors. The stock is currently trading with a P/E ratio of 22.44 and P/B ratio of N/A. Today's performance shows a gain of 0.88%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Bliss GVS Pharma Ltd offers a dividend yield of 0.22%, which means for every ₹100 invested at the current price of ₹213.92, you can expect to receive approximately ₹0.22 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Bliss GVS Pharma Ltd's key financial metrics include: P/E Ratio: 22.44, P/B Ratio: N/A, ROE: 3.92%, ROCE: 11.70%, Dividend Yield: 0.22%, EPS: ₹10.18, Book Value: ₹99.68, Debt-to-Equity: 0.08, and Current Ratio: N/A. The company's market cap stands at ₹2,448.49 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Bliss GVS Pharma Ltd stock opened at ₹204 and is currently trading at ₹213.92, showing a gain of ₹1.87 (0.88%). The intraday high is ₹215.44 and low is ₹204. The trading volume stands at 9,57,140 shares, indicating moderate market participation today.
Bliss GVS Pharma Ltd has a Price-to-Earnings (P/E) ratio of 22.44, which means investors are willing to pay ₹22.44 for every ₹1 of earnings. With an EPS of ₹10.18, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Bliss GVS Pharma Ltd has a market capitalization of ₹2,448.49 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹213.92) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Bliss GVS Pharma Ltd has a book value of ₹99.68 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹213.92, which is 114.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Bliss GVS Pharma Ltd has a Return on Equity (ROE) of 3.92% and Return on Capital Employed (ROCE) of 11.70%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Bliss GVS Pharma Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Bliss GVS Pharma Ltd has a debt-to-equity ratio of 0.08, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Bliss GVS Pharma Ltd has an Earnings Per Share (EPS) of ₹10.18, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹213.92 and P/E ratio of 22.44, investors are paying 22.44 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Bliss GVS Pharma Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Bliss GVS Pharma Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Bliss GVS Pharma Ltd stock, consider: 1) Fundamental Analysis - Review P/E (22.44), ROE (3.92%), debt-to-equity (0.08), and growth rates. 2) Technical Analysis - Check 52-week range (₹108.12 - ₹243.90), moving averages, and chart patterns. 3) Valuation - Compare current price (₹213.92) with book value (₹99.68) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Bliss GVS Pharma Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹213.92 is 21292x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Bliss GVS Pharma Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹108.12 - ₹243.90). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.08 indicates leverage. 4) Liquidity Risk - Based on trading volume of 9,57,140 shares. 5) Valuation Risk - P/E of 22.44 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Bliss GVS Pharma Ltd operates in the industry with key metrics: P/E ratio of 22.44, ROE of 3.92%, market cap of ₹2,448.49 crores, and dividend yield of 0.22%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.08), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Bliss GVS Pharma Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹213.92, with a 52-week range of ₹108.12 to ₹243.90. Based on fundamentals like P/E (22.44), ROE (3.92%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Bliss GVS Pharma Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹213.92. 2) Fundamental Deterioration - Declining ROE (currently 3.92%), increasing debt (D/E: 0.08), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Bliss GVS Pharma Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.22%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.